Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

NCT01688973 PHASE2 COMPLETED Results posted

This randomized phase II trial studies how well tivantinib with or without erlotinib hydrochloride works in treating patients with metastatic or locally advanced kidney cancer that cannot be removed by surgery. Tivantinib and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Details

Lead sponsor	National Cancer Institute (NCI)
Phase	PHASE2
Status	COMPLETED
Enrolment	55
Start date	Mon Aug 20 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Apr 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Recurrent Renal Cell Carcinoma
• Stage III Renal Cell Cancer
• Stage IV Renal Cell Cancer
• Type 1 Papillary Renal Cell Carcinoma
• Type 2 Papillary Renal Cell Carcinoma

Interventions

• Erlotinib Hydrochloride
• Laboratory Biomarker Analysis
• Tivantinib

Countries

United States